In the biotech market, Dexcom DXCM has made several headlines, predominantly due to the company's recent performance, product launches, and legal proceedings. Morgan Stanley has elevated Dexcom's rating to Overweight from Equal weight, and upped its target price to $75. In addition, there is a surge of interest around DXCMβs new diabetes tech launches despite ongoing legal battles. Law firms are urging shareholders to join a securities fraud class action lawsuit against Dexcom, offering potential leadership roles for investors. The company's stock has experienced fluctuations due to other factors such as lawsuits over safety and reliability of its devices and cautious sector forecasts. Despite this, Dexcom has registered significant wins with its CGM-integrated basal insulin tool getting FDA approval and its CGM education forum being introduced in five countries. Dexcomβs Q3 earnings results surpassed estimates while also focusing on strategic innovations.
Dexcom DXCM News Analytics from Wed, 25 Jun 2025 07:00:00 GMT to Sat, 06 Dec 2025 00:12:00 GMT - Rating 2 - Innovation 6 - Information 5 - Rumor -3
